Ardelyx Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
10analysts covering
FY Revenue (est.)
$489.7Mnext fiscal year
FY EPS (est.)
-$0.19next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 1 Nov 2026 |
Monitoring Framework
Key Performance Indicators
IBSRELA Net Product Revenue Quarterly70.1MTarget: $410 million to $430 million (Full Year 2026 Guidance)
XPHOZAH Net Product Revenue Quarterly23.3MTarget: $110 million to $120 million (Full Year 2026 Guidance)
Total Cash, Cash Equivalents and Short-Term Investments Quarterly238.1MTarget: Maintain sufficient liquidity to fund Phase 3 ACCEL trial and commercial operations
Watch Items
- Medicare Part D Coverage and Reimbursement for XPHOZAHTrigger: Exclusion from key Medicare formularies or unfavorable reimbursement decisionsAction: Evaluate commercial strategy adjustments, expand patient assistance programs, and focus on non-Medicare channels
- ACCEL Phase 3 Trial Enrollment for Chronic Idiopathic Constipation (CIC)Trigger: Failure to complete patient enrollment by the end of 2026Action: Increase clinical trial site activation and optimize patient recruitment strategies
Research as of 20 Jun 2026